Pfizer CEO sold shares, after vaccine's effectiveness was announced

Illustration of the Covid-19 vaccine from Pfizer and Biontech.

-

Pfizer CEO Albert Bourla sold US laboratory shares for $ 5.6 million on the day the group announced good preliminary results on the effectiveness of a vaccine against Covid-19 .

According to a document filed with the U.S. Securities and Markets authorities, the official sold 132,508 securities for $ 41.94 on Wall Street, equivalent to nearly $ 5.6 million (or just over $ 4.7 million). euros).

The stock has soared by more than 7%

The vice-president of laboratories, Sally Susman, also sold this Monday for 1.8 million dollars, selling 43,662 titles.

The Pfizer action had soared, the same day, by more than 7% when the American laboratory had announced that its vaccine developed with the German company BioNTech - which had taken 13.91% - was "effective" at 90% against the coronavirus.

Asked about these sales of securities, Pfizer did not respond.

According to a spokesperson quoted on the CNN site, these transactions were already part of a periodic divestment plan put in place by the head of the group when the title reaches a certain price.

Disposals of this amount would have been scheduled as part of their personal financial management, since August 2019 for CEO Albert Bourla and since November 2019 for the vice-president.

Health

Russia claims 92% efficacy for its anti-Covid vaccine

World

Coronavirus: Canada takes option on 56 million doses of Pfizer vaccine

• Health

• Action

• stock Exchange

• Economy

• Laboratory

• Covid 19

• Vaccine